Cost-Effectiveness Analysis in pharmacoeconomics

Cost-Effectiveness Analysis in pharmacoeconomics

In the context of pharmacoeconomics, the cost-effectiveness of a therapeutic or preventive intervention is the ratio of the cost of the intervention to a relevant measure of its effect. Cost refers to the resource expended for the intervention, usually measured in monetary terms such as dollars or pounds. The measure of effects depends on the intervention being considered. Examples include the number of people cured of a disease, the mm Hg reduction in diastolic blood pressure and the number of symptom-free days experienced by a patient. The selection of the appropriate effect measure should be based on clinical judgment in the context of the intervention being considered.

A special case of CEA is cost-utility analysis, where the effects are measured in terms of years of full health lived, using a measure such as quality-adjusted life years or disability-adjusted life years.
Cost-effectiveness is typically expressed as an incremental cost-effectiveness ratio (ICER), the ratio of change in costs to the change in effects.

자료: Wikipedia: Cost-effectiveness analysis

※ 메모:

• quality-adjusted life years(QALYs): "질보정 건강생활년수(가칭)": 어떤 의료적 개입으로 건강을 회복해 생활하는 기간을 생활의 질적 요소를 고려한 가중치를 매겨서 그 햇수를 합산하는 지표다.
• disability-adjusted life years(DALYs): "장애보정 건강상실년수(가칭)"